Answer
Breastfeeding should be avoided during mirvetuximab soravtansine (Elahere) treatment and for 1 month after the last dose because a risk to the newborn or infant cannot be excluded.
Sources for this answer
- ELAHERE 5 mg/mL concentrate for solution for infusionAbbVie Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked